FILTER
LATEST INTERVIEWS
Jose Antonio Moreno Toscano
CEO, LFB USA
LFB speaks to GBR as it begins the commercialization of Sevenfact and ATryn.
Paul Koek
REGIONAL MANAGING DIRECTOR, DIC ASIA PACIFIC
DIC Corporation Asia Pacific continues expansion with the acquisition of BASF’s pigments division.
Arun Nair
MANAGING DIRECTOR APAC, FLUKE RELIABILITY
Fluke Reliability explains how it can help companies connect to an integrated framework of Industrial Internet of Things solutions.
Pedro Damjanic
SENIOR VP - MINING, FINNING
Finning explains how, together with CAT, it is prepared to help Chiles mines move towards autonomy.
Marcial Garcia
PARTNER AND MINING LEAD, EY PERU
EY Peru speaks with GBR about how Peru must reassure mining investors and the implications for mining of the country’s elections this year.
Raúl Ferrero
GENERAL MANAGER, FUCSA – FUNDICIÓN CHILCA S.A.
FUSCA in Chile relates how 2021 is making up for the lost business of 2020.
Michael Gignac
VICE PRESIDENT, FINANCE, G MINING SERVICES
G Mining Services is enjoying strong demand for its services while also looking to own its own precious metals projects.
A. Paul Gill
CEO, LOMIKO METALS INC.
Lomiko Metals speaks to GBR about its’ La Loutre graphite project in Québec.
Salvatore Butti
PRESIDENT, ASSOSALUTE - FEDERCHIMICA
Assosalute represents non-prescription medical products in Italy and explains how easing regulations could be of huge benefit to Italians and the healthcare system.
Paul Carmel
PRESIDENT & CEO, SIDEX
SIDEX explains how it provides financial stimulus to the exploration sector of the Québec mining industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
